Cystic Fibrosis

Affecting over 8,500 people in the UK, Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Around half of the CF population can expect to live over 38 year...

Fibrosis

Cystic Kidney Disease

Fibrosis and Cirrhosis

Congenital Renal Cystic Dysplasia

Powder Tobramycin Okayed for Cystic Fibrosis Lung Infections

Tobramycin inhalation powder joins a solution version that treats the P. aeruginosa lung infections easily acquired by patients with cystic fibrosis. FDA Approvals

FDA Approves TOBI Podhaler to Treat Bacterial Lung Infection in Cystic Fibrosis Patients

The Food and Drug Administration (FDA) has approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes lun...

Mannitol endorsed for cystic fibrosis use

Mannitol inhalation powder (Bronchitol; Pharmaxis) can be prescribed for cystic fibrosis patients who cannot use other treatments...

FDA clears Novartis anti-bacterial inhaler for certain cystic fibrosis patients

Novartis TOBI Podhaler (tobramycin inhalation powder) 28mg per capsule has obtained FDA approval for the treatment of bacterial lung infection in certain cystic fibrosis (CF) patients.

FDA Panel in Favor of Tobramycin Powder in Cystic Fibrosis

An FDA panel voted that tobramycin inhalation powder appears safe and effective in treating Pseudomonas aeruginosa in cystic fibrosis. Medscape Medical News

Inhaler approved for cystic fibrosis patients

(HealthDay)—The TOBI Podhaler (tobramycin inhalation powder) has been approved by the U.S. Food and Drug Administration to treat cystic fibrosis patients infected with Pseudomonas aeruginosa, a bact...

FDA Committee recommends Novartis TIP for cystic fibrosis treatment

The Anti-Infective Drugs Advisory Committee (AIDAC) to the US Food and Drug Administration (FDA) has recommended the use of Novartis's tobramycin inhalation powder (TIP) to treat cystic fibrosis (CF)...

Latest Cystic Fibrosis Market Reports on BioPortfolio.net

Our key pages for cystic fibrosis reports are packed with useful information and links to the latest cystic fibrosis market reports from over 30 of the worlds leading market research companies which...

Mannitol dry powder for inhalation: in patients with cystic fibrosis.

Mannitol dry powder for inhalation has been developed for the treatment of patients with cystic fibrosis. Two randomized, double-blind, multinational, 26-week, phase III trials (CF-301 and CF-302) exa...

New therapies in cystic fibrosis.

Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that lead to abnormalities in transepithelial ion transport in the airways of affected pat...

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: poor adherence and the need to address it.

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Increasing the activity of defective cystic fibrosis transmembrane conductance regulator (CFTR) protein is a potential treatment for cystic fibrosis.

Treatment of cystic fibrosis associated cutaneous vasculitis with chloroquine.

Vasculitis is a well recognised complication of Cystic Fibrosis. Corticosteroids are the mainstay of treatment but some cases can be resistant and may require additional disease modifying agents. We d...